Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Avalon GloboCare

Nasdaq:AVCO
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AVCO
Nasdaq
$84M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Avalon GloboCare has significant price volatility in the past 3 months.
AVCO Share Price and Events
7 Day Returns
-4.3%
NasdaqCM:AVCO
-4%
US Healthcare
-4.1%
US Market
1 Year Returns
-76.4%
NasdaqCM:AVCO
-4.6%
US Healthcare
-14.9%
US Market
AVCO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avalon GloboCare (AVCO) -4.3% -27% -42.2% -76.4% 11% -
US Healthcare -4% -12.9% -18.2% -4.6% 12.3% 13.1%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • AVCO underperformed the Healthcare industry which returned -4.6% over the past year.
  • AVCO underperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
AVCO
Industry
5yr Volatility vs Market

AVCO Value

 Is Avalon GloboCare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Avalon GloboCare. This is due to cash flow or dividend data being unavailable. The share price is $1.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avalon GloboCare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avalon GloboCare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:AVCO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.21
NasdaqCM:AVCO Share Price ** NasdaqCM (2020-04-02) in USD $1.11
United States of America Healthcare Industry PE Ratio Median Figure of 45 Publicly-Listed Healthcare Companies 20.24x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avalon GloboCare.

NasdaqCM:AVCO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AVCO Share Price ÷ EPS (both in USD)

= 1.11 ÷ -0.21

-5.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avalon GloboCare is loss making, we can't compare its value to the US Healthcare industry average.
  • Avalon GloboCare is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Avalon GloboCare's expected growth come at a high price?
Raw Data
NasdaqCM:AVCO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Healthcare Industry PEG Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 1.52x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avalon GloboCare, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avalon GloboCare's assets?
Raw Data
NasdaqCM:AVCO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.10
NasdaqCM:AVCO Share Price * NasdaqCM (2020-04-02) in USD $1.11
United States of America Healthcare Industry PB Ratio Median Figure of 94 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqCM:AVCO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AVCO Share Price ÷ Book Value per Share (both in USD)

= 1.11 ÷ 0.10

11.58x

* Primary Listing of Avalon GloboCare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avalon GloboCare is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Avalon GloboCare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Avalon GloboCare has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AVCO Future Performance

 How is Avalon GloboCare expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avalon GloboCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.5%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avalon GloboCare expected to grow at an attractive rate?
  • Unable to compare Avalon GloboCare's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Avalon GloboCare's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Avalon GloboCare's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:AVCO Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:AVCO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:AVCO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -6 -15
2019-06-30 1 -6 -14
2019-03-31 1 -5 -11
2018-12-31 2 -4 -8
2018-09-30 2 -4 -7
2018-06-30 1 -3 -5
2018-03-31 1 -1 -4
2017-12-31 1 -1 -3
2017-09-30 1 -1 -2
2017-06-30 1 -1 -1
2017-03-31 1 0 0
2016-12-31 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Avalon GloboCare is high growth as no earnings estimate data is available.
  • Unable to determine if Avalon GloboCare is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:AVCO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Avalon GloboCare Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AVCO Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.21
2019-06-30 -0.19
2019-03-31 -0.15
2018-12-31 -0.11
2018-09-30 -0.10
2018-06-30 -0.08
2018-03-31 -0.07
2017-12-31 -0.05
2017-09-30 -0.03
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Avalon GloboCare will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of AVCO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Avalon GloboCare's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Avalon GloboCare's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Avalon GloboCare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avalon GloboCare has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AVCO Past Performance

  How has Avalon GloboCare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avalon GloboCare's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avalon GloboCare does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Avalon GloboCare's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avalon GloboCare's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Avalon GloboCare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avalon GloboCare Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AVCO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.31 -15.27 16.20
2019-06-30 1.37 -13.76 14.18
2019-03-31 1.47 -10.70 11.10
2018-12-31 1.51 -7.77 8.02
2018-09-30 1.54 -6.89 6.26
2018-06-30 1.44 -5.26 4.51
2018-03-31 1.32 -4.40 3.64
2017-12-31 1.08 -3.46 2.70
2017-09-30 1.05 -1.74 1.96
2017-06-30 1.06 -0.82 1.30
2017-03-31 0.68 -0.43 0.87
2016-12-31 0.62 0.06 0.47
2015-12-31 -0.18 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avalon GloboCare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Avalon GloboCare has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avalon GloboCare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avalon GloboCare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avalon GloboCare has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AVCO Health

 How is Avalon GloboCare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avalon GloboCare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avalon GloboCare's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Avalon GloboCare's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Avalon GloboCare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avalon GloboCare Company Filings, last reported 6 months ago.

NasdaqCM:AVCO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 5.75 0.59 1.07
2019-06-30 8.54 1.00 3.40
2019-03-31 9.07 2.00 1.77
2018-12-31 11.25 1.00 2.25
2018-09-30 12.68 1.00 3.81
2018-06-30 10.39 1.45 3.64
2018-03-31 5.81 1.50 2.13
2017-12-31 7.31 1.50 3.03
2017-09-30 2.43 2.41 0.36
2017-06-30 2.80 2.27 0.38
2017-03-31 3.10 0.10 5.43
2016-12-31 3.55 0.00 2.89
2015-12-31 -0.01 0.09 0.11
  • Avalon GloboCare's level of debt (10.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Avalon GloboCare's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Avalon GloboCare has less than a year of cash runway based on current free cash flow.
  • Avalon GloboCare has less than a year of cash runway if free cash flow continues to grow at historical rates of 70.3% each year.
X
Financial health checks
We assess Avalon GloboCare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avalon GloboCare has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AVCO Dividends

 What is Avalon GloboCare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avalon GloboCare dividends.
If you bought $2,000 of Avalon GloboCare shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avalon GloboCare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avalon GloboCare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:AVCO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avalon GloboCare has not reported any payouts.
  • Unable to verify if Avalon GloboCare's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avalon GloboCare's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avalon GloboCare has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avalon GloboCare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avalon GloboCare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avalon GloboCare has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AVCO Management

 What is the CEO of Avalon GloboCare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Jin
COMPENSATION $400,000
AGE 51
CEO Bio

Dr. David K. Jin, M.D., Ph.D., serves as the Chief Executive Officer and President of Avalon Globocare Corp. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medical Institute and Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. He served as the Chief Executive Officer of Global Technologies Corp. since September 14, 2016 and also served as its President since October 10, 2016. He served as the Chief Medical Officer of BioTime, Inc. from 2009 to 2016. He served as the Chief Medical Officer at OncoCyte Corporation. He also worked for the Food and Drug Administration in the United States as Medical Reviewer at the Oncology Product Development Division as well as Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology and stem cell-based technology development. He serves as a Director at Avalon Globocare Corp. He served as a Director of Global Technologies Corp. since September 14, 2016. He is Principle Investigator in more than 15 pre-clinical and clinical trials, as well as an Author/Co-Author of over 80 peer-reviewed scientific abstracts, articles, reviews and book chapters. He received his clinical training and subsequent faculty tenure at the NewYork-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology and clinical oncology. He was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015. Dr. Jin studied Medicine at SUNY Downstate College of Medicine in Brooklyn, NY.

CEO Compensation
  • David's compensation has increased whilst company is loss making.
  • David's remuneration is lower than average for companies of similar size in United States of America.
Management Team

David Jin

TITLE
CEO, President & Director
COMPENSATION
$400K
AGE
51

Luisa Ingargiola

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
52
TENURE
3.2 yrs

Meng Li

TITLE
COO & Secretary
COMPENSATION
$200K
AGE
41

Yu Zhou

TITLE
Co-CEO & Director of GenExsome
COMPENSATION
$182K
Board of Directors Tenure

Average tenure and age of the Avalon GloboCare board of directors in years:

1.8
Average Tenure
51
Average Age
  • The average tenure for the Avalon GloboCare board of directors is less than 3 years, this suggests a new board.
Board of Directors

Daniel Lu

TITLE
Chairman of the Board
AGE
60

David Jin

TITLE
CEO, President & Director
COMPENSATION
$400K
AGE
51

Yu Zhou

TITLE
Co-CEO & Director of GenExsome
COMPENSATION
$182K
TENURE
2.5 yrs

Yancen Lu

TITLE
Independent Director
COMPENSATION
$96K
AGE
44
TENURE
3 yrs

Bill Stilley

TITLE
Independent Director
COMPENSATION
$70K
AGE
51
TENURE
1.8 yrs

Steve Sanders

TITLE
Independent Director
COMPENSATION
$64K
AGE
73
TENURE
1.8 yrs

Jim Gajewski

TITLE
Head of Scientific & Clinical Advisory Board
TENURE
1.7 yrs

Billy Tauzin

TITLE
Director
COMPENSATION
$236K
AGE
75
TENURE
2.4 yrs

Tevi Troy

TITLE
Independent Director
COMPENSATION
$58K
AGE
50
TENURE
1.8 yrs

Shahin Rafii

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Jun 19 Buy Wenzhao Lu Individual 07. Jun 19 07. Jun 19 15,000 $1.84 $27,600
06. Jun 19 Buy Wenzhao Lu Individual 06. Jun 19 06. Jun 19 21,000 $2.03 $42,630
24. Apr 19 Buy Wenzhao Lu Individual 18. Apr 19 18. Apr 19 2,000,000 $1.00 $2,000,000
X
Management checks
We assess Avalon GloboCare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avalon GloboCare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AVCO News

Simply Wall St News

Avalon GloboCare Corp (NASDAQ:AVCO): Time For A Financial Health Check

While small-cap stocks, such as Avalon GloboCare Corp (NASDAQ:AVCO) with its market cap of US$190m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

AVCO Company Info

Description

Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership with Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy; a research and licensing agreement with Massachusetts Institute of Technology to develop technology for cellular therapy; and strategic partnership with GE Healthcare to enhance standardized automation and bio-production for cellular medicines. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.

Details
Name: Avalon GloboCare Corp.
AVCO
Exchange: NasdaqCM
Founded:
$84,105,872
75,771,056
Website: http://www.avalon-globocare.com
Address: Avalon GloboCare Corp.
4400 Route 9 South,
Suite 3100,
Freehold,
New Jersey, 07728,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AVCO New Common Stock Nasdaq Capital Market US USD 20. Oct 2016
Number of employees
Current staff
Staff numbers
9
Avalon GloboCare employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 06:56
End of day share price update: 2020/04/02 00:00
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.